A Phase 2 interventional study of Low Intensity Focused Ultrasound and Sham (No Treatment) in Obsessive Compulsive Disorder, sponsored by University of Pennsylvania. Recruiting at 1 site in United States. Open to participants aged 22 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by University of Pennsylvania · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 299 studies in Obsessive-Compulsive Disorder with a site in United States — 59 open to participants now, 77 under way, 2 of them phase 3. Obsessive-Compulsive Disorder · United States.
Among the 299 studies in Obsessive-Compulsive Disorder with a site in United States, this one is the 122nd largest by planned enrollment of the 246 interventional ones that give a count, is one of 13 that started in 2026, is one of 46 in phase 2, reaches primary completion later than 50 of the 76 other live ones, and was the 296th registered.
637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.
Browse Obsessive-Compulsive Disorder studies →59 of the 299 studies in Obsessive-Compulsive Disorder with a site in United States are open now. Recruiting first, the newest first:
Nader Pouratian · Sites in United States
Ages 22–75
Attune Neurosciences Inc · Sites in United States
Ages 22–80
National Institute of Mental Health (NIMH) · Sites in United States
Ages 10–17 · Healthy volunteers
Francisco A Moreno · Sites in United States
Ages 18+
New York State Psychiatric Institute · Sites in United States
Ages 18–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.
This study: 22 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
299 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 63 · Phase 3 19 · Phase 4 15
First in 1988; this study’s year is marked. 13 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 45 across 522 interventional studies indexed under Obsessive-Compulsive Disorder.
Median enrollment 40 across the 246 interventional studies, 111 across the 50 observational. Of the 201 that completed or were terminated, 74 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 299 have an industry lead sponsor. The 10 most frequent:
University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 229 are open to participants now.
Of its 160 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.
University of Pennsylvania has 3 studies filed under Obsessive-Compulsive Disorder — fewer than ten, so there is no comparison to draw.
29 of the studies in Obsessive-Compulsive Disorder with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05467683Jasper A. SmitsCO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy | 2026-12-01 |
| NCT05783817Carolyn RodriguezMDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) | 2026-12-01 |
| NCT05546658Johns Hopkins UniversityEffects of Psilocybin in Obsessive Compulsive Disorder | 2026-12-30 |
| NCT03918577Stanford UniversityCaloric Vestibular Stimulation for Modulation of Insight in Obsessive-Compulsive Spectrum Disorders | 2026-12-30 |
| NCT05651295Matthew Southward, PhDA Precision Medicine Approach to Target Engagement for Emotion Regulation | 2026-12-31 |
Add all 29 to your calendar (.ics) → With an account.
Among the 299 studies in Obsessive-Compulsive Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study tests ATTN201, an investigational non-invasive headband that delivers low-intensity focused ultrasound (LIFU) to the subthalamic nucleus (STN) as a treatment for obsessive-compulsive disorder (OCD). It's a randomized, double-blind, 1:1 (active: sham) study with 40 total participants spanning 12-16 weeks and 14 in-person and remote visits.
This is a randomized, double-blind, sham-controlled study evaluating the safety and feasibility of ATTN201, an investigational, non-invasive, wearable ultrasound headband, in adults with obsessive-compulsive disorder (OCD). ATTN201 uses low-intensity focused ultrasound (LIFU), guided by magnetic resonance imaging (MRI), to deliver stimulation to the subthalamic nucleus (STN), a brain region implicated in OCD symptom circuits. This is the fifth study in which ATTN201 has been used in humans, and the device is not currently approved by the U.S. Food and Drug Administration (FDA) for clinical use outside of research.
Approximately 40 participants will be enrolled in this study, ages 18-80, will be enrolled at a single site in San Francisco. Participants will be randomly assigned in a 1:1 ratio to receive either active focused ultrasound stimulation (20 participants) or sham (inactive) stimulation (20 participants). Sham stimulation sounds the same as active stimulation but does not deliver a therapeutic ultrasound effect to the brain. Neither participants nor the study staff administering treatment will know which group a participant has been assigned to during the treatment period.
Participation lasts approximately 12 to 16 weeks and includes 14 in-person and remote visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female participants who are sexually active agree to use two methods of contraception for the duration of the study or not be of as indicated by one of the following:
Exclusion Criteria:
Has any for completing a brain MRI scan.
a. The subject's head must fit within the head coil (32 or 64 channel), while wearing the MR-compatible device.
Has a recent or ongoing, uncontrolled, medical condition where participation in the trial would pose a significant medical risk to the subject or would confound study results within 3 months of Screening, such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ATTN201 focused ultrasound stimulation delivered to the subthalamic nucleus (STN)
Device: Low Intensity Focused Ultrasound
ATTN201 sham/unfocused stimulation - device is fitted and produces the same audible sound as active stimulation but delivers no substantive focused ultrasound effect to the brain.
Device: Sham (No Treatment)
ATTN201 is an investigational, non-invasive, wearable headband containing two ultrasound transducers positioned over the temporal region of the skull. Guided by a pre-treatment MRI, the device delivers focused low-intensity ultrasound (LIFU) to the subthalamic nucleus (STN).
Also known as: LIFU
Participants are fitted with the same ATTN201 headband used in the active arm, and the device is operated using the same procedures and audible output as active stimulation. However, the ultrasound is unfocused and does not deliver a therapeutic effect to the brain. This sham condition is designed to be indistinguishable from active stimulation to preserve blinding of participants and study staff.
Change in OCD symptom severity
Measured by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
Time frame: up to 3 months
Incidence and severity of adverse events
Device-related and procedure-related side effects
Time frame: up to 3 months
Change in Anxiety Symptoms
Beck Anxiety Inventory
Time frame: up to 3 months
Change in depressive symptoms
Beck Depression Inventory - II (BDI-II)
Time frame: up to 3 months
Change in global impression
Clinical global impression severity and clinical global impression improvement
Time frame: up to 3 months
Change in functional disability
Sheehan Disability Scale
Time frame: up to 3 months
session-level symptom change
Visual Analog Scale ratings collected at each study intervention session
Time frame: up to 3 months
Change in resting-state and task based functional connectivity
fMRI
Time frame: up to 3 months
Plan to share: No
Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Obsessive-Compulsive Disorder →